CARM
Price
$0.40
Change
+$0.08 (+25.00%)
Updated
Sep 5 closing price
Capitalization
16.79M
CYTK
Price
$53.01
Change
+$3.26 (+6.55%)
Updated
Sep 5 closing price
Capitalization
6.34B
54 days until earnings call
Interact to see
Advertisement

CARM vs CYTK

Header iconCARM vs CYTK Comparison
Open Charts CARM vs CYTKBanner chart's image
Carisma Therapeutics
Price$0.40
Change+$0.08 (+25.00%)
Volume$7.12M
Capitalization16.79M
Cytokinetics
Price$53.01
Change+$3.26 (+6.55%)
Volume$3.72M
Capitalization6.34B
CARM vs CYTK Comparison Chart in %
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. CYTK commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a StrongBuy and CYTK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (CARM: $0.40 vs. CYTK: $53.01)
Brand notoriety: CARM and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 63% vs. CYTK: 193%
Market capitalization -- CARM: $16.79M vs. CYTK: $6.34B
CARM [@Biotechnology] is valued at $16.79M. CYTK’s [@Biotechnology] market capitalization is $6.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 5 TA indicator(s) are bullish while CYTK’s TA Score has 4 bullish TA indicator(s).

  • CARM’s TA Score: 5 bullish, 5 bearish.
  • CYTK’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CARM is a better buy in the short-term than CYTK.

Price Growth

CARM (@Biotechnology) experienced а +86.93% price change this week, while CYTK (@Biotechnology) price change was +50.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($6.34B) has a higher market cap than CARM($16.8M). CYTK YTD gains are higher at: 12.691 vs. CARM (-4.035). CARM has higher annual earnings (EBITDA): -44.04M vs. CYTK (-504.83M). CYTK has more cash in the bank: 858M vs. CARM (2M). CARM has less debt than CYTK: CARM (1.7M) vs CYTK (858M). CYTK has higher revenues than CARM: CYTK (85.7M) vs CARM (10.8M).
CARMCYTKCARM / CYTK
Capitalization16.8M6.34B0%
EBITDA-44.04M-504.83M9%
Gain YTD-4.03512.691-32%
P/E RatioN/AN/A-
Revenue10.8M85.7M13%
Total Cash2M858M0%
Total Debt1.7M858M0%
FUNDAMENTALS RATINGS
CARM vs CYTK: Fundamental Ratings
CARM
CYTK
OUTLOOK RATING
1..100
3083
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5439
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CARM's Valuation (92) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CARM’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that CYTK’s stock grew similarly to CARM’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that CYTK’s stock grew similarly to CARM’s over the last 12 months.

CYTK's Price Growth Rating (39) in the Biotechnology industry is in the same range as CARM (54) in the null industry. This means that CYTK’s stock grew similarly to CARM’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CARM (100) in the null industry. This means that CYTK’s stock grew significantly faster than CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMCYTK
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 25 days ago
83%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KYTX3.940.31
+8.54%
Kyverna Therapeutics
AAPG40.501.92
+4.97%
Ascentage Pharma Group
IR80.951.75
+2.21%
Ingersoll Rand
CTLP10.81-0.04
-0.37%
Cantaloupe
AIMD3.49-0.14
-3.86%
AINOS Inc

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with EVGN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then EVGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
+25.59%
EVGN - CARM
58%
Loosely correlated
+0.25%
INSM - CARM
45%
Loosely correlated
+1.80%
KZIA - CARM
35%
Loosely correlated
-4.08%
CYTK - CARM
33%
Loosely correlated
+6.55%
PMVP - CARM
33%
Loosely correlated
+1.39%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with MLYS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then MLYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+6.55%
MLYS - CYTK
54%
Loosely correlated
+5.07%
CRNX - CYTK
45%
Loosely correlated
+3.97%
ROIV - CYTK
44%
Loosely correlated
+2.78%
IMVT - CYTK
44%
Loosely correlated
+6.33%
ARWR - CYTK
43%
Loosely correlated
+3.84%
More